Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sutro Biopharma Inc

0.7538
-0.0094-1.23%
Volume:527.21K
Turnover:395.94K
Market Cap:63.67M
PE:-0.25
High:0.7726
Open:0.7600
Low:0.7302
Close:0.7632
Loading ...

Sutro Biopharma Inc. : Deutsche Bank Cuts Target Price to $5 From $10

THOMSON REUTERS
·
17 Mar

Sutro Biopharma presents expanded data from REFRalphaME-01 trial

TIPRANKS
·
17 Mar

Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
16 Mar

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

TipRanks
·
15 Mar

Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ...

GuruFocus.com
·
15 Mar

Sutro Biopharma Cut to Market Perform From Market Outperform by Citizens Capital Markets

Dow Jones
·
14 Mar

Nasdaq Surges 1.5%; Ulta Beauty Posts Upbeat Results

Benzinga
·
14 Mar

Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8

MT Newswires Live
·
14 Mar

Sutro Biopharma Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $2 From $8

THOMSON REUTERS
·
14 Mar

Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs

GuruFocus.com
·
14 Mar

Truist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)

TIPRANKS
·
14 Mar

Sutro Biopharma Inc : Wedbush Cuts to Neutral From Outperform; Cuts Target Price to $2 From $8

THOMSON REUTERS
·
14 Mar

Sutro Biopharma Cut to Underperform From Buy by B of A Securities

Dow Jones
·
14 Mar

Truist Removes $15 Price Target From Sutro Biopharma, Keeps Buy Rating

MT Newswires Live
·
14 Mar

Sutro Biopharma downgraded to Underperform from Buy at BofA

TIPRANKS
·
14 Mar

Sutro Biopharma Names New CEO; Plans to Reduce Workforce by Nearly 50% After Portfolio Review

MT Newswires Live
·
14 Mar

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sutro Biopharma (STRO) and Generation Bio (GBIO)

TIPRANKS
·
14 Mar

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
14 Mar

Sutro Biopharma Review Results in 50% Workforce Reduction, CEO Transition

Dow Jones
·
14 Mar

Sutro Biopharma FY 2024 GAAP EPS $(2.96) Misses $(2.92) Estimate, Sales $62.043M Beat $59.004M Estimate

Benzinga
·
14 Mar